Related Experiment Video
Updated: Dec 18, 2025
Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
Published on: March 18, 2014
Identification of Lysosome-Associated Protein Transmembrane-4 as a Novel Therapeutic Target for Osteosarcoma
Zhe-Xiang Wang1, Meng-Yang Guo1, Jing Ren2
1School of Medical Laboratory, Tianjin Medical University, Tianjin, China.
Objective:
The aim of the study is to evaluate the expression of lysosome-associated protein transmembrane-4 (LAPTM4B) in human osteosarcoma tissue samples collected in our hospital, and to explore the possible correlations between the clinical pathological features of osteosarcoma patients and LAPTM4B expression.
Methods:
Immunohistochemical (IHC) assays were performed to detect the expression levels of LAPTM4B in 62 tissue samples of osteosarcoma tissues and corresponding non-tumor tissues. According to LAPTM4B staining intensity in tumor tissues, osteosarcoma patients were classified into LAPTM4B high expression and low expression groups. In addition, the potential correlations between LAPTM4B expression levels and clinical pathological features were evaluated. In addition, we detected the effects of LAPTM4B on the proliferation and invasion of esteosarcoma cells through colony formation assay and transwell assay, respectively. We further explored the potential effects of LAPTM4B on tumor growth and metastasis using in vivo animal model.
Results:
We revealed that LAPTM4B was highly expressed in human osteosarcoma tissues. We determined the significance between LAPTM4B and clinical features, including the tumor size (P = 0.004*) and the clinical stage (P = 0.035*) of osteosarcoma patients. Our results further demonstrated that ablation of LAPTM4B obviously blocked the proliferation and invasion of osteosarcoma cells in vitro and restrained tumor growth and metastasis in mice.
Conclusion:
We investigated the potential involvement of LAPTM4B in osteosarcoma progression and confirmed LAPTM4B as a novel therapeutic target for osteosarcoma.
Insights
Lysosome-associated protein transmembrane-4 (LAPTM4B) is highly expressed in osteosarcoma, correlating with tumor size and stage. Inhibiting LAPTM4B suppressed osteosarcoma cell proliferation and metastasis, identifying it as a potential therapeutic target.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Osteosarcoma is a primary bone malignancy with significant metastatic potential.
- Lysosome-associated protein transmembrane-4 (LAPTM4B) is implicated in various cancers, but its role in osteosarcoma remains unclear.
Purpose of the Study:
- To investigate LAPTM4B expression in human osteosarcoma tissues.
- To explore the correlation between LAPTM4B expression and clinicopathological features of osteosarcoma.
- To evaluate the functional role of LAPTM4B in osteosarcoma cell proliferation, invasion, and metastasis.
Main Methods:
- Immunohistochemical (IHC) analysis of LAPTM4B expression in 62 osteosarcoma and non-tumor tissue samples.
- In vitro assays including colony formation and Transwell assays to assess proliferation and invasion.
- In vivo animal models to evaluate the impact of LAPTM4B on tumor growth and metastasis.
Main Results:
- LAPTM4B was significantly upregulated in osteosarcoma tissues compared to non-tumor tissues.
- High LAPTM4B expression correlated with larger tumor size (P = 0.004) and advanced clinical stage (P = 0.035).
- Ablation of LAPTM4B inhibited osteosarcoma cell proliferation and invasion in vitro and suppressed tumor growth and metastasis in vivo.
Conclusions:
- LAPTM4B plays a crucial role in osteosarcoma progression.
- LAPTM4B represents a promising novel therapeutic target for osteosarcoma treatment.
More Related Videos
11:15A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells
Published on: May 6, 2018
07:31A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
Published on: May 3, 2021
